Related Experiment Video
Updated: May 16, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Antidiabetic and lipid-lowering medication use inversely linked with serum biomarkers of liver fibrosis
Jun Wang1, Dora Ding1, Xiaorong Shao1
1Gilead Sciences, Inc, Foster City, California, USA.
Aims:
The impact of antidiabetic and lipid-lowering medications on fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) is poorly understood. We evaluated associations between the use of these medications and serum liver fibrosis biomarkers, and whether they vary by genetic factors.
Materials And Methods:
This cross-sectional study used baseline medication and fibrosis biomarker (aspartate aminotransferase-to-platelet ratio index [APRI], Enhanced Liver Fibrosis [ELF], Fibrosis-4 Index (FIB-4) and FibroSure/FibroTest) data from two phase 3 trials (N = 1649) of MASH with bridging fibrosis (NCT03053050, N = 785) or compensated cirrhosis (NCT03053063, N = 864). A weighted polygenic risk score (wPRS) for MASH was derived for participants of European ancestry (N = 742) using six genetic variants. Least-squares means and 95% confidence interval (CIs) were derived using multivariable linear regression.
Results:
Combined use of antidiabetic and lipid-lowering medications was associated with statistically significantly lower adjusted mean ELF (-0.34 [95% CI: -0.47, -0.20] or - 3.2%), FIB-4 (-0.53 [95% CI: -0.74, -0.32] or - 18.0%), APRI (-0.27 [95% CI: -0.37, -0.18] or - 23.1%) and FibroSure/FibroTest scores (-0.08 [95% CI: -0.11, -0.06] or - 14.7%) compared with nonuse. Among participants of European ancestry, the inverse association for FIB-4 (interaction p = 0.01) or APRI (interaction p = 0.004) was stronger in participants with high (>median) versus low (≤median) wPRS; no significant interactions were observed for ELF or FibroSure/FibroTest.
Conclusions:
Antidiabetic and lipid-lowering medication use was associated with lower serum liver fibrosis biomarkers. Among participants with European ancestry, associations between combined use of these medications and lower FIB-4 or APRI scores were stronger in those at high genetic risk of MASH. Longitudinal studies are warranted to extend upon these potentially clinically important findings.
More Related Videos
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Dipeptidyl Peptidase 4 Inhibitors
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...